Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines

Oncogene

Volumn 23, Issue 20, 2004, Pages 3541-3549

  Cronauer, Marcus V ^a   Schulz, Wolfgang A ^a   Burchardt, Tatjana ^a   Ackermann, Rolf ^a   Burchardt, Martin ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Androgen receptor; MDM2; p53; Pifithrin; Probasin promoter; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; PIFITHRIN 1ALPHA; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; WILD TYPE;

HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2442693040     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207346     Document Type: Article

References (57)

1. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW and Scher HI. (1999). J. Natl. Cancer Inst., 91, 1869-1876.
2. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z and Cordon-Cardo C. (1994). J. Urol., 151, 1276-1280.
3. Asschert JG, De Vries EG, De Jong S, Withoff S and Vellenga E. (1999). Int. J. Cancer, 81, 236-242.
4. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, de la Taille A, Kiss A and Buttyan R. (2001). Prostate, 48, 225-230.
5. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD and Parl FF. (1994). Cancer, 73, 2147-2155.
6. Carroll AG, Voeller HJ, Sugars L and Gelmann EP. (1993). Prostate, 23, 123-134.
7. Chen T, Wang LH and Farrar WL. (2000). Cancer Res., 60, 2132-2135.
8. Coffey RNT, Watson RWG, O'Neill AJ, Mc Eleny K and Fitzpatrick JM. (2002). Prostate, 53, 300-309.
9. Coursen JD, Bennett WP, Khan MA, Forrester K, Pietenpol JA and Harris CC. (1997). Mol. Carcinogen., 19, 191-203.
10. Culig Z, Bartsch G and Hobisch A. (2002). Mol. Cell. Endocrinol., 197, 231-238.
11. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G and Klocker H. (1993). Mol. Endocrinol., 7, 1541-1550.
12. Cronauer MV, Eder IE, Hittmair A, Sierek G, Hobisch A, Culig Z, Thurnher M, Bartsch G and Klocker H. (1997). In Vitro Cell Dev. Biol. Anim., 33, 742-744.
13. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G and Culig Z. (2000). Br. J. Cancer, 82, 39-45.
14. Eastham JA, Grafton W, Martin CM and Williams BJ. (2000). J. Urol., 164, 814-819.
15. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT and Thompson TC. (1995). Clin. Cancer Res., 1, 1111-1118.
16. Feldman BJ and Feldman D. (2001). Nat. Rev., 1, 34-44.
17. Freedland SJ, Pantuk AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso C-L and Belldegrun AS. (2003). Prostate, 55, 299-307.
18. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S and Howley PM. (1998). Mol. Cell, 2, 405-415.
19. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E and Gudkov AV. (2002). Oncogene, 2, 153-157.
20. Hasse A, Schulz WA and Siess H.. (1992). Biochem. Biophys. Acta, 1131, 16-22.
21. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP and Brown TJ. (1997). Mol. Cell. Endocrinol., 126, 59-73.
22. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H and Culig Z. (1998). Cancer Res., 58, 4640-4645.
23. Isaacs WB, Carter BS and Ewing CM. (1991). Cancer Res., 51, 4716-4720.
24. Jacobberger JW, Sramkoski RM, Zhang D, Zumstein LA, Doerksen LD, Merritt JA, Wright SA and Shults KE. (1999). Cytometry, 38, 201-213.
25. Javelaud D and Besancon F. (2002). J. Biol. Chem., 277, 37949-37954.
26. Kelly KJ, Plotkin Z, Vulgamott SL and Dagher PC. (2003). J. Am. Soc. Nephrol., 14, 128-138.
27. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV. (1999). Science, 285, 1733-1737.
28. Komarova EA, Neznanov N, Komarov PG, Chernov MV, Wang K and Gudkov A. (2003). J. Biol Chem., 278, 15465-15468.
29. Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM and Kopnin BP. (1997). Oncol. Res., 9, 155-166.
30. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R and Pienta KJ. (2001). In Vivo, 15, 157-162.
31. Lin H-Y, Shih AI, Davis FB, Tang H-Y, Martino LJ, Bennett JA and Davis PJ. (2002a). J. Urol., 168, 748-755.
32. Lin H-K, Wang L, Hu Y-C, Altuwaijri S and Chang C. (2002b). EMBO J., 21, 4037-4048.
33. Makri D, Schulz WA, Grimm M-O, Clasen S, Bojar H and Schmitz-Dräger BJ. (1998). Int. J. Oncol., 12, 621-628.
34. Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE and Daxenbichler G. (1990). Cancer Res., 50, 7037-7041.
35. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD and deVere White RW. (1998). Cancer, 83, 2534-2539.
36. Momand J, Zambetti GP, Olson DC, George D and Levine AJ. (1992). Cell, 69, 1237-1245.
37. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC and Conti CJ. (1993). J. Natl. Cancer Inst., 85, 1657-1669.
38. Nesslinger NE, Shi X-B and deVere White RW. (2003). Cancer Res., 63, 2228-2233.
39. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C. (1999). Clin. Cancer Res., 5, 2082-2088.
40. Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL and Belldegrun AS. (2000). J. Urol., 164, 1420-1425.
41. Peehl DM. (1994). Atlas of Human Tumor Cell Lines, Hay RJ, Park J-G, Gazdar A (eds) Academic Press: London, pp. 387-411.
42. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B and Remvikos Y. (1996). Oncogene, 12, 875-882.
43. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW and Weichselbaum RR. (1991). J. Surg. Oncol., 46, 31-36.
44. Runnebaum IB, Tong XW, Mobus VJ, Kieback DG, Rosenthal HE and Kreienberg R. (1994). FEBS Lett., 353, 29-32.
45. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C and McDonnell TJ. (2001). Int. J. Cancer, 91, 159-166.
46. Sengupta S and Wasylyk B. (2001). Genes Dev., 15, 2367-2380.
47. Shaulian E, Zauberman A, Ginsberg D and Oren M. (1992). Mol. Cell. Biol., 12, 5581-5592.
48. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K and Shemshedini L. (2001). J. Biol. Chem., 276, 38472-38479.
49. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH and deVere White RW. (2002). Prostate., 51, 59-72.
50. Sinisi AA, Chieffi P, Pasquali D, Kisslinger A, Staibano S, Bellastella A and Tramontano D. (2002). In Vitro Cell Dev. Anim., 38, 165-172.
51. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW. (1999). In Vitro Cell Dev. Biol. Anim., 35, 403-409.
52. Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul JW, Cowan KH and Seth P. (1995). Urology, 46, 843-848.
53. Steinhoff C, Prior A, Reichmann G, Seifert HH and Schulz WA. (2002). Int. J. Oncol., 21, 1033-1040.
54. Tepper CG, Boucher DL, Ryan PE, Ma A-H, Xia L, Lee L-F, Pretlow TG and Kung H-J. (2002). Cancer Res., 62, 6606-6614.
55. Yap N, Yu CL and Cheng SY. (1996). Proc. Natl. Acad. Sci. USA, 93, 4273-4277.
56. Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH and Cheng S. (1997a). Biochem. Biophys. Res. Commun., 239, 520-617.
57. Yu C, Yap N, Chen D and Cheng S. (1997b). Cancer Lett., 116, 191-196.